A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

This study is testing a drug called SHR-A1811 — an antibody-drug conjugate that targets the HER2 protein — as a first-line treatment for people with advanced or metastatic non-small cell lung cancer (NSCLC) that carries a HER2 mutation. These HER2 mutations are a driver of cancer growth in a subset of lung cancers. **You may be eligible if...** - You are between 18 and 75 years old - You have advanced or metastatic NSCLC confirmed by biopsy - Your tumor has been confirmed to carry a functional HER2 mutation by a central laboratory - You have not yet received any systemic treatment for your advanced or metastatic NSCLC - You are in generally good health (ECOG 0–1) - You have at least one measurable tumor outside the brain on imaging - Your heart, kidney, liver, and blood count results are within acceptable ranges **You may NOT be eligible if...** - Your lung cancer has a small cell component or sarcomatoid features - Your cancer also has another driver mutation that has an approved targeted therapy available - You have active or untreated brain or spinal cord metastases - You have poorly controlled pain from the tumor - You have had or currently have another cancer - You have a history of serious lung inflammation or pneumonitis Talk to your doctor to see if this trial is right for you.